Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430716 · ClinicalTrials.gov registry record · Phase 4
To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Terminated
- Registry status
- Phase 4
- Development phase
- 130
- Enrollment target
NCT00430716 is a Phase 4 study that was terminated before completion, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 130 participants.
The verdict
NCT00430716, a Phase 4 study, was terminated before completion, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 130 participants
- Enrollment target
Study Summary
To demonstrate a dose response for 1 mg, 5 mg and 20 mg TID oral sildenafil for the treatment of subjects with PAH.
Interventions
- DRUG Sildenafil citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2008-04-08 |
| Est. Completion | 2010-05-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00430716
The ClinicalTrials.gov registry entry for NCT00430716 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sildenafil citrate is the first listed.
NCT00430716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00430716 about?
NCT00430716 is a clinical study titled "To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.". To demonstrate a dose response for 1 mg, 5 mg and 20 mg TID oral sildenafil for the treatment of subjects with PAH.
What is the current status of trial NCT00430716?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 130 participants. The study started on 2008-04-08. Estimated completion is 2010-05-25.
What interventions are being tested in trial NCT00430716?
The interventions under investigation include: Sildenafil citrate (DRUG).
Who is sponsoring clinical trial NCT00430716?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.